Insurance, genetic testing and familial cancer: recent policy changes in the United Kingdom.
作者信息
Morrison P J
出版信息
Ulster Med J. 2001 Nov;70(2):79-88.
Abstract
摘要
相似文献
1
Insurance, genetic testing and familial cancer: recent policy changes in the United Kingdom.
Ulster Med J. 2001 Nov;70(2):79-88.
2
Genetic testing and insurance in the United Kingdom.
Clin Genet. 1998 Nov;54(5):375-9. doi: 10.1111/j.1399-0004.1998.tb03749.x.
3
Insurance, unfair discrimination, and genetic testing.
Lancet. 2005;366(9489):877-80. doi: 10.1016/S0140-6736(05)67298-4.
4
GINA update.
J Cardiovasc Transl Res. 2008 Mar;1(1):9-10. doi: 10.1007/s12265-008-9013-5. Epub 2008 Feb 21.
5
Genetic testing.
Genet Test. 2008 Jun;12(2):175-6. doi: 10.1089/gte.2008.1500.
6
Genetic antidiscrimination laws in health insurance: a misguided solution.
Quinnipiac Health Law J. 2001;4(2):149-210.
7
The Genetic Nondiscrimination in Health Insurance and Employment Act: H.R. 602.
N Y Law Sch J Hum Rights. 2001;18(1):1-11.
8
Genetic predispositions, prophylactic treatments and private health insurance: nothing is better than a good pair of genes.
Am J Law Med. 1997;23(1):45-68.
9
Genetic discrimination in health insurance--comprehensive legal solutions for a (not so) special problem?
Indiana Health Law Rev. 2005;2(1):1-47.
10
Regulatory approaches to genetic testing in insurance.
Syd Law Rev. 2002 Jun;24(2):189-206.
引用本文的文献
1
The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status.
Fam Cancer. 2006;5(2):201-4. doi: 10.1007/s10689-006-6990-x.
2
Hereditary non-polyposis colon cancer.
Ulster Med J. 2005 May;74(1):14-21.
3
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
Br J Cancer. 2004 Nov 15;91(10):1787-94. doi: 10.1038/sj.bjc.6602207.
本文引用的文献
1
Genetic testing, adverse selection, and the demand for life insurance.
Am J Med Genet. 2000 Jul 3;93(1):29-39.
2
Health, life and disability insurance and hereditary risk for breast or colorectal cancer.
Acta Oncol. 2000;39(2):189-93. doi: 10.1080/028418600430752.
3
Factors influencing health insurers' decisions to cover new genetic technologies.
Int J Technol Assess Health Care. 2000 Winter;16(1):178-89. doi: 10.1017/s026646230016115x.
4
Laws restricting health insurers' use of genetic information: impact on genetic discrimination.
Am J Hum Genet. 2000 Jan;66(1):293-307. doi: 10.1086/302714.
5
Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe.
Dis Markers. 1999 Oct;15(1-3):159-65. doi: 10.1155/1999/748254.
6
Cancer genetics services in Europe.
Dis Markers. 1999 Oct;15(1-3):3-13. doi: 10.1155/1999/134945.
7
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Eur J Cancer. 1998 Nov;34(12):1922-6. doi: 10.1016/s0959-8049(98)00288-3.
8
Implications of genetic testing for insurance in the UK.
Lancet. 1998 Nov 21;352(9141):1647-8. doi: 10.1016/s0140-6736(05)61446-8.
9
Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom.
BMJ. 1998 Dec 12;317(7173):1632-5. doi: 10.1136/bmj.317.7173.1632.
10
Genetic testing and insurance in the United Kingdom.
Clin Genet. 1998 Nov;54(5):375-9. doi: 10.1111/j.1399-0004.1998.tb03749.x.
Zotero 插件